Effect of the parameters regulation of the nanoparticulate form of doxorubicin based on PLGA on the distribution between human blood plasma and red blood cells
- Authors: Kovshova T.S1,2, Osipova N.S2, Belov A.V2, Maksimenko O.O2, Balabanyan V.Y.1, Gelperina S.E2
-
Affiliations:
- M.V. Lomonosov Moscow State University
- D. Mendeleev University of Chemical Technology of Russia
- Issue: Vol 23, No 8 (2020)
- Pages: 11-18
- Section: Articles
- URL: https://journals.eco-vector.com/1560-9596/article/view/112769
- DOI: https://doi.org/10.29296/25877313-2020-08-02
- ID: 112769
Cite item
Abstract
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
T. S Kovshova
M.V. Lomonosov Moscow State University; D. Mendeleev University of Chemical Technology of Russia
Email: kovshova.tatyana.nanofarm@gmail.com
Post-graduate Student; Research Scientist
N. S Osipova
D. Mendeleev University of Chemical Technology of RussiaResearch Scientist
A. V Belov
D. Mendeleev University of Chemical Technology of RussiaPh.D. (Chem.), Research Scientist
O. O Maksimenko
D. Mendeleev University of Chemical Technology of RussiaPh.D. (Chem.), Research Scientist
V. Yu Balabanyan
M.V. Lomonosov Moscow State UniversityDr.Sc. (Pharm.), Leading Research Scientist
S. E Gelperina
D. Mendeleev University of Chemical Technology of RussiaDr.Sc. (Chem.), Professor
References
- Wacker M. Nanocarriers for intravenous injection - the long hard road to the market. Int. J. Pharm. 2013; 457(1):50-62.
- Gelperina S., Maksimenko O., Khalansky A.S., Vanchugova L., Shipulo E. et al. Drug delivery to the brain using surfactant coated poly (lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur. J. Pharm. Biopharm. 2010: 74(2):157-163.
- Pereverzeva E., Treschalin I.D., Treschalin M.I., Arantseva D. et al. Toxicological study of doxorubicin-loaded PLGA nanoparticles for the treatment of glioblastoma. Int. J. Pharm. 2019; 554:161-178.
- Maksimenko O., Malinovskaya Ju., Shipulo E., Osipova N., Razzhivina V. et al. Doxorubicin-loaded PLGA nanoparticles for the chemotherapy of glioblastoma: Towards the pharmaceutical development. Int. J. Pharm. 2019; 572: 118733.
- Kumskova N., Ermolenko Yu., Osipova N., Semyonkin A., Kildeeva N. et al. How subtle differences in polymer molecular weight affect doxorubicin-loaded PLGA nanoparticles degradation and drug release. J. Microencapsul. 2020; 37(3):283-295.
- Yu S., Li Sh., Yang H., Lee F., Wu J. T., Qian M.G.et al. A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery. Rapid Commun. Mass. Spectrom. 2005; 19(2):250-254.
- Tewes F., Munnier E., Antoonet B., Okassa L.N., Cohen-Jonathan S. et al. Comparative study of doxorubicin-loaded poly (lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods. Eur. J. Pharm. Biopharm. 2007; 66(3):488-492.
- Zelepukin I.V., Yaremenko A.V., Shipunova V.O., Babenyshev A.V., Balalaeva I.V. et al. Nanoparticle-based drug delivery via RBC-hitchhiking for the inhibition of lung metastases growth. Nanoscale. 2019; 11(4):1636-1646.
- Kalamaridis D., DiLoreto K. Drug partition in red blood cells. Optimization in Drug Discovery. Humana Press. Totowa, NJ. 2014; р. 39-47.
- Terasaki T., Iga T., Sugiyama M., Hanano M. Pharmacokinetic study on the mechanism of tissue distribution of doxorubicin: interorgan and interspecies variation of tissue-to-plasma partition coefficients in rats, rabbits, and guinea pigs. J. Pharm. Sci. 1984; 73(10):1359-1363.
- Colombo T., Broggini M., Garattini S., Donelli M.G. Diferential a driamycin® distribution to blood components. Eur. J. Drug Metab. Pharmacokinet. 1981;6(2):115-122.
Supplementary files
![](/img/style/loading.gif)